articles link to it . please introduce links to this page from related articles ; try the find link tool for suggestions . march 2010 tigenix nv type public euronext tig industry biotechnology founded 2000 headquarters leuven belgium key people eduardo bravo ceo number of employees 70 website http www.tigenix.com tigenix euronext tig is a european cell therapy company with a proprietary validated allogeneic expanded adipose derived stem cell easc platform technology for the treatment of autoimmune and inflammatory diseases and a commercialised product . its corporate headquarters are in leuven belgium and it has operations in madrid spain . tigenix was founded in 2000 by prof. dr. frank p. luyten and gil beyen as a spin off from the katholieke universiteit leuven and the universiteit gent . 1 tigenix s therapeutic approach is to focus on the use of living cells rather than conventional drugs for the treatment of inflammatory and autoimmune diseases through its easc based platform and heart disease through its csc based platform . tigenix s pipeline of stem cell programs is based on validated platforms of allogeneic stem cells . as of march 31 2016 tigenix s pipeline portfolio 2 was the most advanced cell therapy platform in europe with positive pivotal phase iii data for its lead product candidate and three further product candidates in phases ii and i and pre clinical development . tigenix has completed and received positive data in a single pivotal phase iii trial in europe of its most advanced product candidate cx601 a potential first in class injectable allogeneic stem cell therapy indicated for the treatment of complex perianal fistulas in patients suffering from crohn s disease . on july 28 2016 the lancet 3 published the 24 week results of the phase 3 admire cd trial investigating cx601 in the treatment of complex perianal fistulas in patients with crohn s disease . cx601 has been granted orphan designation by the european medicines agency in recognition of its potential application for the treatment of anal fistulas which affect approximately 120 000 adult patients in the united states and europe and for which existing treatment options are inadequate . tigenix developed and commercialized chondrocelect the first cell based medicinal product to receive marketing authorization from the ema which was indicated for cartilage repair in the knee . in july 2016 tigenix requested the withdrawal of its marketing authorization for chondrocelect . references edit http flandersbio.be life sciences database tigenix multiple product candidates . the lancet of publishes 24 week results of the phase 3 admire cd trial investigating cx601 in the treatment of complex perianal fistulas in patients with crohn s disease . external links edit tigenix website tigenix has been a rollercoaster de tijd 14 may 2014 kanaal z report july 2014 cx601 could be launched in 2017 l echo 3 july 2014 tigenix on kanaal z television tigenix at alliance for regenerative medicine meeting march 2015 retrieved from https en.wikipedia.org w index.php title tigenix & oldid 733446377 categories biotechnology companies of belgium2000 establishments in belgiumhidden categories orphaned articles from march 2010all orphaned articles navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 7 august 2016 at 21 30 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view